Oasmia registers $23 million of stock for initial public sale of ADS

Bookrunner Ladenburg Thalmann helps fund clinical trials, development

By Devika Patel

Knoxville, Tenn., July 6 – Oasmia Pharmaceutical AB will price its initial public offering of American Depositary Shares with a 45-day greenshoe, according to a Form F-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $23 million of underlying ordinary stock.

Each ADS represents two ordinary shares.

Ladenburg Thalmann is the bookrunner.

Proceeds will be used for clinical trials, development, capital expenditures and other general corporate purposes.

The pharmaceutical company is based in Uppsala, Sweden. The company intends to list the ADS on the Nasdaq under the symbol “OASM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.